NTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nutrien Ltd is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators, options data, and recent analyst downgrades suggest limited short-term upside. While the company has shown strong financial performance in the latest quarter, the broader sentiment and potential pricing pressures in the potash market make it prudent to hold off on buying at this time.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 38.562, and moving averages are converging, showing no clear trend. The stock is trading near the S1 support level of 73.128, with resistance at 78.151. Overall, technical indicators suggest a cautious outlook.
Strong financial performance in Q4 2025, with revenue up 5.14% YoY, net income up 405.31% YoY, and EPS up 413.04% YoY. Analysts like BMO, CIBC, and Wells Fargo have raised price targets, citing potential near-term pricing strength in fertilizers due to geopolitical factors.
UBS downgraded the stock to Sell, citing downside risk and pricing pressures in the potash market. Hedge funds are selling, with a 116.85% increase in selling activity. Technical indicators show bearish momentum, and the stock has a 40% chance of declining in the short term.
In Q4 2025, Nutrien's revenue increased to $5.34 billion, up 5.14% YoY. Net income surged to $571 million, up 405.31% YoY, and EPS rose to 1.18, up 413.04% YoY. Gross margin improved to 35.36%, up 13.59% YoY, indicating strong profitability growth.
Mixed ratings with recent downgrades. UBS downgraded to Sell with a $67 target, citing downside risks. However, BMO, CIBC, and Wells Fargo raised price targets to $90, $90, and $100, respectively, citing near-term pricing strength. Jefferies upgraded to Buy with a $96 target due to geopolitical factors. Overall, analysts are divided, with some concerns about long-term pricing pressures.
